At 8:00 on September 12, 2021 at Beijing Anding Hospital, the investigators successfully completed the first dose group administration of ZZ6398 in healthy subjects.
ZZ6398, an innovative drug with a new mechanism of action targeting cognitive associated with schizophrenia, is the first Class I new drug entered into clinical trial for schizophrenia by ZHONGZE. In animal studies, ZZ6398 has good efficacy on positive symptoms, negative symptoms and cognitive dysfunction of schizophrenia. The complete pharmacological and toxicologicaldata show that the safety and efficacy of ZZ6398 was superior to a blockbuster schizophrenia drug.
Zhongze is looking forward to the successful completion of a Phase I clinical trial of ZZ6398.